The Quebec Family Study (QFS): Role of Genetic Factors in Obesity and Its Related Risk Factors and Diseases

Completed

• Conditions: Physical Fitness; Obesity

• Registration Number: NCT03355729
• Lead Sponsor: Louis Pérusse

Brief Summary

The Quebec Family Study (QFS) is an observational study that was planned to investigate the role of genetic factors in physical fitness, body composition, risk factors for common disease and health-related behaviour.

Detailed Description

The Quebec Family Study was an observational study with three cycles of data collection between 1978 and 1992. During the first cycle of data collection (Phase 1: 1978-1982), a total of 1,650 subjects from 375 families were recruited. During the second cycle (Phase 2: 1989-1997), 385 subjects from 105 phase 1 families were retested and an additional 372 subject from 74 families were recruited. During the third cycle (Phase 3: 1998-2002), 204 subjects from phase 1 were tested a third time, 113 subjects from phase 2 were tested a second time and 194 new subjects from 44 families were recruited.

Study Timeline

• Study Start: 1978-06
• Primary Completion: 2002-09-05
• Study Completion: 2002-09-05
• Status Verified: 2017-11
• Study First Submitted: 2017-11-16
• Study First Submitted QC: 2017-11-27
• Last Update Submitted: 2017-11-27
• Study First Posted: 2017-11-28
• Last Update Posted: 2017-11-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 951

Inclusion Criteria

• Age over 10 years

Exclusion Criteria

• Not applicable

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Abdominal fat	Through study completion, an average of 24 years	Abdominal fat as assessed by commuted tomography
Waist and hip circumferences (cm)	Through study completion, an average of 24 years	Waist and hip circumferences (cm)
Body composition	Through study completion, an average of 24 years	Body composition as assessed by underwater weighing
Body mass index (kg/m^2)	Through study completion, an average of 24 years	Body mass index assessed from height and weight

Secondary Outcome Measures

Name	Time	Method
Physical activity level	Through study completion, an average of 24 years	Physical activity level assessed by questionnaire
Plasma lipid levels (mmol/L)	Through study completion, an average of 24 years	Fasting levels of triglycerides, LDL-cholesterol and HDL-cholesterol in mmo/L
Alcohol consumption	Through study completion, an average of 24 years	Alcohol consumption (nb of drinks per week)
Caloric intake	Through study completion, an average of 24 years	Total caloric intake and macronutrient intake using a 3-day dietary record
Adiponectin levels (in micrograms/ml)	Through study completion, an average of 24 years	Adiponectin levels (in micrograms/ml)
Energy expenditure	Through study completion, an average of 24 years	Oxygen consumption at rest and during exercise
Smoking habits (nb of cigarettes per day)	Through study completion, an average of 24 years	Smoking habits (nb of cigarettes per day)
Blood pressure (mm Hg)	Through study completion, an average of 24 years	Systolic and diastolic blood pressure
Glucose levels (mmol/L)	Through study completion, an average of 24 years	Plasma glucose levels in a fasting state and following an oral glucose tolerance test, inflammatory markers.; Plasma glucose levels in a fasting state and during an oral glucose tolerance test
C-reactive protein (CRP in mg/ml)	Through study completion, an average of 24 years	C-reactive protein (CRP in mg/ml)
Sleeping (hours/day)	Through study completion, an average of 24 years	Sleeping (hours/day)
Eating behaviour	Through study completion, an average of 24 years	Eating behaviour assessed using the Three-Factor Eating questionnaire
Insulin levels (pmol/L)	Through study completion, an average of 24 years	Plasma insulin levels in a fasting state and following an oral glucose tolerance test.
Interleukin-6 (IL6) and tumor necrosis factor-alpha (TNF-alpha) in pg/ml	Through study completion, an average of 24 years	Interleukin-6 (IL6) and tumor necrosis factor-alpha (TNF-alpha) in pg/ml